New experimental vaccine produces immune response against MERS virus

April 30, 2014, University of Maryland
MERS-CoV particles as seen by negative stain electron microscopy. Virions contain characteristic club-like projections emanating from the viral membrane. Credit: Centers for Disease Control and Prevention

The University of Maryland School of Medicine (UM SOM) and Novavax, Inc. today announced that an investigational vaccine candidate developed by Novavax against the recently emerged Middle East Respiratory Syndrome Coronavirus (MERS-CoV) blocked infection in laboratory studies. UM SOM and Novavax also reported that a vaccine candidate against Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) developed by Novavax on a similar platform also inhibited virus infection. Researchers reported these findings in an article published in the April 13, 2014 issue of Vaccine.

Historically, strategies for emerging pathogens have been limited due to the sudden nature in which the virus first appears and delayed by the protracted traditional process. This peer-reviewed manuscript describes a novel method to rapidly develop vaccines against previously unknown viruses, such as MERS-CoV, which appear suddenly and cause severe illnesses in humans. The experimental vaccines, which were tested in conjunction with Novavax' proprietary adjuvant Matrix-M, induced neutralizing antibodies, or immune responses, that prevent viruses from infecting cells.

"Our protein nanoparticle vaccine technology is proving to have the potential to respond rapidly to emerging viruses such as MERS-CoV and certain potential pandemic influenza strains, addressing what are clearly urgent public health needs," said Gale Smith, Ph.D., Vice President of Vaccine Development at Novavax. "Novavax will continue to evaluate this technology to produce highly immunogenic nanoparticles for coronavirus, influenza, and other human disease pathogens with the potential for pandemic and sustained human to human transmission."

"The emergence of SARS-CoV and MERS-CoV demonstrates how coronaviruses can spillover from animals into humans at any time, causing lethal disease," said Matthew B. Frieman, Ph.D., Assistant Professor of Microbiology and Immunology at the University of Maryland School of Medicine and corresponding author on the publication. "Despite efforts to create a vaccine against SARS-CoV, no vaccine candidate has, to date, been successfully licensed for use. We have demonstrated that this novel method rapidly creates SARS-CoV and MERS-CoV vaccines that induce neutralizing antibodies in mice."

"The University of Maryland School of Medicine investigators are continually working toward a better understanding of the interactions between the human immune system and a variety of known and novel harmful microbes," said E. Albert Reece, Vice President of Medical Affairs, the University of Maryland and the John Z. and Akiko Bowers Distinguished Professor and Dean, University of Maryland School of Medicine. "This makes our faculty poised to respond to emerging infectious diseases, such as MERS-CoV, which threaten the health and wellbeing of the global population."

The were made using Novavax' recombinant nanoparticle vaccine technology and based on the major surface spike (S) protein, a SARS-CoV and MERS-CoV surface protein responsible for attaching the virus to cells. Novavax previously demonstrated that spike protein nanoparticles could protect animals against lethal live challenge using the SARS-CoV virus.

Explore further: Scientists identify antibodies against MERS

More information: C. M. Coleman et al. Purified coronavirus Spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. Vaccine. In press, April 13, 2014.

Y. Liu et al. Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV, 2011; 29(38): 6606-6613.

Related Stories

Scientists identify antibodies against MERS

April 28, 2014
Scientists at Dana-Farber Cancer Institute have identified natural human antibodies against the virus that causes Middle East Respiratory Syndrome (MERS), a step toward developing treatments for the newly emerging and often-fatal ...

Candidate vaccine against MERS passes first test

September 6, 2013
In collaboration with colleagues in Rotterdam, an LMU research team led by Professor Gerd Sutter has produced the first candidate vaccine against the MERS virus, a novel and highly pathogenic coronavirus.

Middle East respiratory syndrome coronavirus has not yet reached pandemic potential

July 4, 2013
New estimates of the transmissibility of the Middle East respiratory syndrome coronavirus in humans suggest that it does not yet have pandemic potential, according to research published in The Lancet.

Double attack on SARS

August 28, 2012
After the SARS-CoV (severe acute respiratory syndrome coronavirus) outbreak in 2003, academia experts in immunology and molecular biology joined forces with industrial vaccine production experts in order to develop preventive ...

SARS virus treatments could hold the key for treatment of MERS-CoV outbreak

September 13, 2013
A new type of coronavirus, the Middle East Respiratory Syndrome Coronavirus, MERS-CoV, was first found a year ago in a patient who died. It took several months before it was discovered that a new virus had emerged. New cases ...

Live virus implicates camels in MERS outbreak

April 29, 2014
There is new, more definitive evidence implicating camels in the ongoing outbreak of Middle East Respiratory Syndrome, or MERS. Scientists at the Center for Infection and Immunity at Columbia University's Mailman School of ...

Recommended for you

Researchers discover key driver of atopic dermatitis

January 17, 2018
Severe eczema, also known as atopic dermatitis, is a chronic inflammatory skin condition that is driven by an allergic reaction. In their latest study, researchers at La Jolla Institute reveal an important player that promotes ...

Who might benefit from immunotherapy? New study suggests possible marker

January 16, 2018
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments.

Researchers identify new way to unmask melanoma cells to the immune system

January 16, 2018
system, which enables these deadly skin cancers to grow and spread.

How the immune system's key organ regenerates itself

January 15, 2018
With advances in cancer immunotherapy splashing across headlines, the immune system's powerful cancer assassins—T cells—have become dinner-table conversation. But hiding in plain sight behind that "T" is the organ from ...

Immunosuppressive cells in newborns play important role in controlling inflammation in early life

January 15, 2018
New research led by The Wistar Institute, in collaboration with Sun Yat-sen University in China, has characterized the transitory presence of myeloid-derived suppressor cells (MDSCs) in mouse and human newborns, revealing ...

Memory loss from West Nile virus may be preventable

January 15, 2018
More than 10,000 people in the United States are living with memory loss and other persistent neurological problems that occur after West Nile virus infects the brain.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.